PND20 Improving Clinical Outcomes and Health Care Resources Utilization in Multiple Sclerosis: A Portuguese Hospital Perspective  by Viriato, D. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A393
of shunt infections uses a disproportionate amount of hospital expenditure (71% of 
total management costs or € 57,650 per patient) when compared to shunt revision 
surgery (29% of total costs or € 6,720 per patient). Using shunt implant data from 
the UK Hospital Episode Statistics (HES), procedures and interventions database, 
we estimated the potential cost savings to the UK Health Care system in 2012-13 
was £1,461,207 if all new lumboperitoneal or ventriculoperitoneal shunt surgeries 
were performed using AISC systems. ConClusions: Current clinical evidence has 
demonstrated AISC reduce infection rates in shunted Hydrocephalus patients. The 
potential health care savings associated with reduced infection rates are significant.
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objeCtives: In recent years, fingolimod and natalizumab - though expensive - have 
brought significant improvements in second-line treatment of Multiple Sclerosis 
(MS). In Italy, fingolimod was acknowledged in 2011 the therapeutic innovation 
criterion which exempts the manufacturer from a mandatory discount of 5% on 
the ex-factory price for a three-year period. Since the innovation period is soon 
expiring and in order to assess the affordability of this therapy for the National and 
Regional Healthcare Systems (HSs), we performed a Budget Impact Analysis (BIA) 
of fingolimod in second-line treatment of MS, enclosed an ethical assessment of 
justice issues. Methods: A model in MSExcel was built to perform the BIA on five 
Regions located in the Nord, Centre and South of Italy. Interviews with regional 
stakeholders/clinicians provided information about epidemiology, market share, 
patient journey and resource consumption in the respective regions. Costs were 
calculated using regional tariffs for outpatient/inpatient health care services. The 
time horizon is three years which is the timeframe mostly requested by Healthcare 
Authorities. Results: Preliminary results conducted for Lazio and Sicily show that, 
in second line, the use of fingolimod compared to natalizumab leads to savings of 
€ 2,500 per patient in Lazio and € 2,700 in Sicily due to lower consumption of health 
care resources (different drug administration and patient management). The BIA 
shows that fingolimod can determine savings up to € 3.4 million approximately 
in Lazio and € 2.2 million in Sicily. Furthermore, if patients with frequent relapses 
in first line were early switched to second line, savings could be even higher: an 
additional € 2.0 million for Lazio and € 0.6 million for Sicily in the first year of treat-
ment. ConClusions: The present analysis shows that, despite innovation expiry, 
spending remains sustainable for fingolimod in the Italian and Regional HSs. 
Analyses on the other Regions must be performed to confirm such results.
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objeCtives: Relapsing-remitting multiple sclerosis (RRMS), the most common 
form of MS, imposes a considerable cost burden on health care systems. Glatiramer 
acetate 20mg/mL, a once-daily injectable disease modifying therapy (DMT), has 
long-term real-world efficacy (more than two million patient/years exposure) for 
the treatment of RRMS. An economic model was developed to estimate the financial 
impact on the UK health care system of switching RRMS treatments from glati-
ramer acetate to emerging oral (teriflunomide and dimethyl fumarate) and infused 
(alemtuzumab) DMTs over five years. Methods: The eligible patient population 
in the model was estimated based on RRMS incidence rates, and the proportion 
of people receiving glatiramer acetate in the UK in 2013 (based on market share 
data). Medication costs were derived from British National Formulary list prices, 
while treatment administration, initiation and monitoring costs were calculated 
from UK health care unit and hospital tariff codes taking account of requirements 
specified in Summary of Product Characteristics documentation. Results: The 
model estimated that 5,900 people with RRMS were receiving glatiramer acetate in 
the UK in 2013, corresponding to 17.8% of those currently receiving DMTs. Assuming 
progressive switching within the eligible RRMS population from glatiramer acetate 
to teriflunomide (from 1–6% in year one to five), dimethyl fumarate (1–6%) and 
alemtuzumab (1–3%), additional spending of £17.0 million, £65.3 million and £147.6 
million over one, three and five years, respectively, was incurred. This was primarily 
driven by higher acquisition costs compared with glatiramer acetate. Administration 
requirements associated with alemtuzumab, and the initiation and monitoring 
requirements of the oral DMTs also contributed to additional costs. ConClusions: 
No data exist supporting the clinical superiority – and therefore associated eco-
nomic benefit – of the emerging DMTs over glatiramer acetate; switching patients 
from glatiramer acetate to new therapies may be associated with substantial costs 
for the UK health care system.
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objeCtives: In Portugal there are about 2,694 patients treated with interferon 
beta (IFNB) and it is estimated that 30.4% are poor responders. Fingolimod treat-
ment costs are an obstacle to treatment escalation, despite the fact that early 
initiation of fingolimod may impact favorably on long-term clinical outcomes. 
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objeCtives: To summarize rates of prevalence, incidence and types of multiple 
sclerosis (MS) in Latin America. Methods: We searched Medline, Embase, Scielo 
and LILACS using key words “multiple sclerosis” and “esclerosis múltiple”, plus 
“Latin America” and all country names. Accepted were full articles or abstracts 
reporting original research in any language at any time, with MS diagnosed using 
any acceptable criteria. Clinically isolated syndrome was excluded. Results: 1482 
articles were identified and 203 reviewed in full; 88 were rejected and 115 were 
analyzed (38 prevalence, 3 incidence, 2 both, 72 clinical epidemiology), including 
68 (59%) full text and 47 (41%) abstracts. Studies originated in 14 countries, mostly 
larger, more affluent nations (47% Brazil, 15% Argentina, 8% Mexico). Prevalence 
studies examined 19,357 MS cases from 1968-2012; rates ranged from 0 in a group 
of Mexican natives to 52/100,000 in Puerto Rico, with a mean of 13.9/100,000. This 
range would be classified as low to medium, with 83,000 (CI95%: 62,000-104,000) 
prevalent cases in Latin America. Incidences ranged from 0.15/100,000 person-
years in Panama to 1.76 in Argentina (median= 1.32, mean= 1.35), or 7,887-8,365 new 
cases/year in Latin America. Authors noted increasing prevalence and incidence 
rates over time. Clinical epidemiology MS data were obtained from 94 studies; 66% 
used Poser criteria, 48% McDonald (various versions), and 14% other, from 19,893 
patients (72% females). The average age at assessment was 38.2 and 32.2 at disease 
onset with average EDSS of 3.1. The relapsing-remitting form was most prevalent 
(74% of cases), followed by secondary progressive (12%) and primary progressive 
(10%). ConClusions: MS prevalence and incidence rates vary widely in Latin 
America in a low to medium range, but are increasing as reported in the reviewed 
studies. Information is scant with many gaps. More research is needed to provide 
a basis for decision making and budget allocation.
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objeCtives: The association between Parkinson’s disease (PD) and prostate can-
cer (PCA) is under discussion. We investigated whether exposure to entacapone 
increases risk of PCA by comparing PCA incidence and mortality rates in PD patients 
treated with levodopa and dopa decarboxylase inhibitors (DDCIs) with or without 
entacapone as an adjuvant. Methods: This was a retrospective population-based 
register cohort study in Finland. Male PD patients exposed to levodopa/DDCI with 
entacapone and patients on levodopa/DDCI without entacapone between 1998 and 
2009 were identified from the Finnish Prescription Register. Concomitant treat-
ment with dopamine agonists (DA) and monoamine oxidase B (MAO-B) inhibitors 
was allowed. PCA cases and PCA deaths were identified from the Finnish Cancer 
Register and from the Cause of Death Register. PCA Incidence and mortality of 
PCA were modeled by Cox’s proportional hazards model with adjustments for rel-
evant baseline and time-dependent variables. The robustness of the findings for 
PCA incidence was evaluated in sensitivity analyses with alternative definitions 
for exposure and by using a nested case-control study setting with 4-5 individually 
matched controls randomly selected for each incident prostate cancer case within 
the cohort. Results: The study cohort consisted of 11 396 male patients. During a 
mean follow-up time of 4.7 years 359 PCA cases and 89 PCA deaths were observed. 
Entacapone use with levodopa/DDCI did not increase the risk of PCA incidence 
[hazard ratio (HR) 1.05, 95% CI 0.76-1.44] or PCA mortality (HR 0.93,95% CI 0.43-1.98) 
when compared to levodopa/DDCI without entacapone. For cumulative entacapone 
use (exposure > 360 days vs. never use) the HR was 0.82 (95% CI 0.56-1.18) for PCA 
incidence and 1.27 (95% CI 0.60-2.72) for PCA mortality. The results for PCA incidence 
were found robust in the sensitivity analyses. ConClusions: No increased risk in 
PCA incidence or PCA mortality was seen in relation to entacapone use.
NeuRologIcal DIsoRDeRs – cost studies
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bACkgRound: Shunt infections are one of the most serious and costly compli-
cations associated with shunt therapy. They can have long-term consequences 
to the patient and impose significant burden on the family and health care sys-
tem. objeCtives: To investigate the clinical and economic value of AISC in the 
treatment of Hydrocephalus. Methods: A search of the Embase, PubMed, and NHS 
EED electronic databases was conducted to identify studies evaluating the effective-
ness, efficacy and economic aspects of AISC’s in patients with Hydrocephalus. No 
language restrictions were applied. Results: Twenty-three clinical and 9 economic 
studies were included for review. The majority of published studies using AISC 
in the treatment of hydrocephalus demonstrated a statistically significant reduc-
tion in shunt-associated infections when AISC vs. standard shunt (SS) catheters 
were used. One meta-analysis of 14 studies that compared patients implanted with 
AISC to SS catheters showed AISC to be protective against shunt infection in both 
paediatric and adult Hydrocephalus patients. The pooled infection rate decreased 
from 7.0% in the SS catheter group to 3.5% in the AISC group. Economic studies 
conducted globally reported significant cost savings associated with using AISC. 
One study in paediatric Hydrocephalus patients found that ongoing management 
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Embase, Scielo and LILACS using the key words “multiple sclerosis” and “esclerosis 
múltiple” plus “Latin America” and all country names. Full articles or abstracts from 
meetings reporting original research on cost or economic analyses, budget impact 
or resource utilization were obtained. No restrictions were placed on publication 
date or language. All work was done in duplicate by two independent reviewers 
with adjudication by consensus discussion. Results: We identified 1482 papers, 
of which 27 were considered for analysis. There were 7 economic analyses (5 cost-
effectiveness, 2 cost-utility), 5 budget impact analyses, 10 cost analyses (6 drug 
expenditures and 4 cost of illness), 4 on resource utilization and 1 on productivity 
loss. Studies were obtained from 5 countries (18 Brazil, 3 Argentina, 3 Colombia, 2 
Mexico, 1 Chile). Mostly (22/27, 81%) were published as abstracts; 5 were published 
as full text articles (19%). Dates for these publications ranged from 2002 to 2013, 
with an exponential increase over time. The number of MS patients is increasing 
rapidly (71% increase in Brazil between 2006 and 2009). However, hospitalization 
rates (overall and per patient) have been decreasing, as newer more effective drugs 
have been increasingly used. Disease modulating therapies are predominantly 
used. Costs of care are quite high and have risen dramatically, e. g. > 200% in Brazil 
between 2007-2012, with beta-interferons mostly used (78%). Some high cost drugs 
such as fingolimod and natalizumab have been found cost-effective over older drugs 
such as beta-interferons or glatiramer acetate in Mexico, Brazil and Colombia, with 
modest impact on budgets. ConClusions: Very little evidence related to cost of 
MS has been produced in Latin America. More research is needed to better support 
decisions regarding care of MS patients.
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objeCtives: Alzheimer’s disease has a substantial economic impact on patients, 
their caregivers and society. There are four cognitive enhancers commonly used in 
the treatment of Alzheimer’s disease: three cholinesterase inhibitors (donepezil, 
rivastigmine and galantamine) and one NMDA receptor antagonist (memantine). 
Studies have indicated that the cost of cholinesterase treatment may be offset by 
savings in other health care costs. Methods: The cost of medication on the South 
African market for Alzheimer’s disease was analysed using June 2014 retail prices 
with the Defined Daily Dose (DDD) as unit cost indicator. A retrospective drug uti-
lisation study was conducted on prescription data of a medical insurance scheme 
administrator for 2012. Results: The cost per DDD for memantine was R26.20 
(20 mg, two 10 mg tablets). For rivastigmine, the cost was R41.02 per DDD and for 
galantamine R27.72 per DDD (using the most convenient dosage strengths). These 
three products were all originator products. For donepezil, the originator and three 
branded generics were available. The cost of the originator was R27.86 per DDD, and 
for all three generics R16.29 per DDD. Only 32 patients were included in the drug 
utilisation study since not all medical aids reimburse these products. The aver-
age age of patients was 74.17 (SD= 9.54) years, with 50% females. Only memantine 
and donepezil were prescribed. Donepezil accounted for 77.48% of prescriptions 
(of which 60.93% were generic prescriptions). The average Prescribed Daily Doses 
(PDDs) were 16.30 (SD= 4.92) mg for memantine and 8.73 (SD= 2.84) mg for donepezil. 
The most frequent PDDs for memantine was 20 mg (62.96% of prescriptions) and 
10 mg (37.04% of prescriptions), and for donepezil 10 mg (65.96% of prescriptions) 
and 5 mg (29.79% of prescriptions). ConClusions: More South African studies on 
Alzheimer’s disease treatment cost are needed that include the stage of the disease 
and adherence to treatment.
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objeCtives: Several commonly prescribed enzyme-inducing anti-epileptic drugs 
(EIAEDs) stimulate the synthesis of some hepatic enzymes responsible for drug 
metabolism. This synthesis can lead to complications by altering endogenous 
metabolic pathways or by affecting the elimination of concomitant drugs thus 
increasing health care costs. This study aimed to systematically review published 
estimates of direct and indirect costs associated with the use of EIAEDs compared 
with non-enzyme-inducing anti-epileptic drugs (nEIAEDs) in patients with focal 
and generalised seizures, and to evaluate methodological differences between the 
studies. Methods: Comprehensive electronic searches were undertaken using 
MEDLINE, EMBASE, Cochrane Library, EconLit, relevant conference proceedings 
and cost effectiveness analysis registries. All studies reporting any direct and 
indirect costs of AEDs for the treatment of patients with epileptic seizures were 
included. Study quality assessment was performed for every included study 
using a predesigned check list. Results: Thirty-seven full-length articles and 
two abstracts reporting costs were reviewed. Two studies reported AED costs, 
drug-specific adverse event costs and non-drug health care costs subsequent to 
the initiation of each individual AED (medical visits, MRI scans, etc.). Six studies 
reported specific AED costs and the overall subsequent non-drug health care cost 
without stratification by event. Eighteen studies reported AED acquisition costs 
but did not report any other subsequent AED-related health care costs stratified 
by treatment. Thirteen studies reported the whole cost of illness with only a list 
of AEDs included. To date, no study has been specifically designed to compare 
the total costs between EIAED and nEIAED use, although some studies compared 
direct and indirect costs of several newer AEDs versus older AEDs. ConClusions: 
Insufficient data and heterogeneity in methodology prevent valid comparisons 
being made between the total cost of EIAEDs and nEIAEDs. More research is 
required to identify if meaningful differences in the total cost of treatment exist 
between EIAEDs and nEIAEDs.
This analysis aimed to assess if the early switch from IFNB to fingolimod impacts 
MS clinical outcomes and promotes better resource utilization in a Portuguese 
hospital perspective. Methods: This analysis was based on TRANSFORMS phase 
III trial extension data. A cost-effectiveness model was developed to calculate the 
cost per relapse avoided with 4.5 years of continuous treatment with fingolimod 
(early treatment) versus 1 year of treatment with IFNB followed by a 3.5 years of 
treatment with fingolimod (delayed treatment). A Portuguese hospital perspec-
tive was adopted addressing only direct costs: drug, monitoring and relapses’ 
treatment. Drug costs were based on Portuguese list prices, while the unit cost 
of each complication was obtained from the Diagnosis Related Groups tariff. The 
costs of relapses were derived from the Portuguese literature. Results: Assuming 
there are 819 patients treated with IFNB that are poor responders, the early treat-
ment with fingolimod resulted in more relapses avoided when compared with 
delayed treatment with fingolimod (2,211 versus 1,843). The early treatment with 
fingolimod led to an increase of drug acquisition costs, but reduced costs asso-
ciated to monitoring and relapses’ treatment. The total costs were 86,380,820€ 
for early treatment versus 79,257,091€ for delayed treatment. This represents an 
average incremental investment of 1,933€ per patient per year. The early strategy 
resulted an incremental cost effectiveness ratio of 19,358€ per relapse avoided 
when compared with the delayed strategy. ConClusions: Under the Portuguese 
hospital perspective, early treatment with fingolimod is expected to result in 
better clinical outcomes associated with a more efficient health care resources 
allocation.
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objeCtives: Intrathecal baclofen (ITB) therapy is indicated for use in the manage-
ment of intractable spasticity. Patients treated with ITB are required to receive a 
pump refill at least once every three months in the hospital (standard care (SC)). 
Since SC can be very burdensome for both patients and informal caregivers, an 
alternative approach (Care4homecare) has been developed which enables patients 
to receive pump refills at home. Moreover, the use of specially trained nurse prac-
titioners ensures that there is no reduction in effectiveness. We compared the 
costs of both strategies. Methods: Resource use in both strategies was estimated 
using observational data of 38 adult patients with spasticity (due to e. g. multiple 
sclerosis or spinal cord injury) that are currently living at home. We then com-
bined this data with expert opinion and the Dutch costing manual to estimate 
the total one-year costs from a societal perspective. Results: Patients included 
in the analysis had on average an age of 52±14.4 years, 50% was men and patients 
scored on average 44±12.5 points on the Care Dependency Scale. The Care4homecare 
strategy involves care that is almost identical to SC and therefore can result in 
comparable direct medical costs. However, patients receiving Care4homecare do 
not incur any travel costs compared with SC patients (€ 489). In addition, the pro-
ductivity costs of informal caregivers (SC € 195; Care4homecare € 40) and of patients 
treated with Care4homecare are less than the costs of patients receiving SC. From 
a societal perspective, the total costs of Care4homecare can be lower than that of 
SC. ConClusions: Care4homecare is an alternative approach to treat patients 
with intrathecal baclofen that can be cost-neutral from a health care sector per-
spective and cost-saving from a societal perspective. Moreover, it can be a welcome 
option for many patients and caregivers who want to avoid the burden of regular 
hospital visits.
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objeCtives: To analyze the costs associated with first-line use of glatiramer acetate 
(GA) compared to interferon-B (INF-β ) in patients with relapsing-remitting multiple 
sclerosis (RRMS) and spasticity from the perspective of the National Health System 
of Spain. Methods: A cost analysis of treatment and spasticity management with 
INF-β compared to GA for 6 months were analyzed. The clinical data were taken from 
the ESCALA study, which showed an improvement in spasticity in terms of spasm 
frequencies, muscle tone, and pain 3 and 6 months after the start of GA therapy. 
Unit costs for the resources used were taken from the BOTPLUS 2.0 database and 
available literature. The cost analysis is expressed in euros as of 2014, and a price 
discount of 7.5% was applied as set forth in Spanish Royal Decree 8/2010. Results: 
The costs associated with the management of RRMS, spasticity, and relapses using 
GA and INF-β were € 4,671.31 and € 7,078.02, respectively, generating a cost savings 
of € 2,406.72/patient, in favour of GA. ConClusions: The use of AG in the first-
line treatment of patients with RRMS not only improves spasticity but it could be 
a strategy that offers savings cost after 6 months from the start of treatment. To 
initiate the treatment with AG and keep it in patients with optimal response would 
be a more efficient treatment option than INF-β .
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objeCtives: To summarize published articles dealing with economic issues related 
to multiple sclerosis (MS) in Latin America. Methods: We searched Medline, 
